Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
about
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeProfile of sarilumab and its potential in the treatment of rheumatoid arthritis.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to dateReal-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases
P2860
Q33775593-47C56318-DFE6-4C09-ABD9-6EACFA539BEDQ38745066-155CA345-DAA1-4FDA-ADE8-3739814BAAA4Q38988087-1324D81D-52FB-4C14-A8CD-6B9D31643853Q40179378-23666D1A-E378-41B7-9CAC-C9B3B0521B41Q40556448-FB16AA4A-4593-4161-AC05-116D03133F09Q47106974-2F12B997-6C84-4A29-B640-2DE9CDFB11BCQ47693399-524E3788-9DE3-4609-B1D0-82D5AB50ACBCQ47810854-DAD75612-BE05-4BF8-BA69-2688794A2FB6Q52653996-4C66D609-3B11-44C9-BE55-E240A25F280BQ54998113-016B15BA-4304-4791-A64C-9F2614259F68Q58750029-F27895BD-CB62-49C0-B60E-DD3CA9FC0E29
P2860
Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@ast
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@en
type
label
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@ast
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@en
prefLabel
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@ast
Twelve-Year Retention Rate of ...... fe Data From a Local Registry.
@en
P2093
P2860
P50
P356
P1476
Twelve-Year Retention Rate of ...... ife Data From a Local Registry
@en
P2093
Alessandra Emiliana Penatti
Antonio Marchesoni
Francesca Pregnolato
Martina Biggioggero
P2860
P304
P356
10.1002/ACR.22788
P577
2016-04-01T00:00:00Z